Details of the Drug Combinations

General Information of This Drug (ID: DMFMBZ4)

Drug Name

Zanamivir DMFMBZ4

Synonyms

zanamivir; 139110-80-8; Relenza; 4-Guanidino-Neu5Ac2en; GANA; Zanamavir; MODIFIED SIALIC ACID; GG167; UNII-L6O3XI777I; GG 167; GR-121167X; Zanamivir (Relenza); Relenza (TN); 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid; GR 121167X; CHEMBL222813; L6O3XI777I; ZMR; CHEBI:50663; GANA (inhibitor); 5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid; GNA; AK163166; GG-167; DSSTox_CID_3749; DSSTox_RID_77184; DSSTox_GSID_23749; Zanamivir [USAN:INN:BAN]; HSDB 7437; C12H20N4O7; GANA; Zanamivir hydrate; GR121167X; Zanamivir (USAN/INN); (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; 4-Guanidino-NeueAc2en; 5-(acetylamino)-4-{[amino(imino)methyl]amino}-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid; ZNV; 4-guanidino-Neu5Ac2en; BAC-zanamivir

Indication

Disease Entry	ICD 11	Status	REF
Influenza	1E30-1E32	Approved	[1]
Influenza virus infection	1E30-1E32	Approved	[2]
Severe acute respiratory syndrome (SARS)	1D65	Investigative	[3]
------------------------------------------------------------------------------------

Therapeutic Class

Antiviral Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Zanamivir + Oseltamivir	DC6LXUE	Oseltamivir	Influenza	[4]
Zanamivir + Zanamivir	DC7XZZ6	Zanamivir	Influenza A Virus, H1N1 Subtype	[5]
------------------------------------------------------------------------------------

References

1	Zanamivir FDA Label
2	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 021036
3	Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis. 2004 Apr;10(4):581-6. doi: 10.3201/eid1004.030458.
4	ClinicalTrials.gov (NCT00921726) Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults
5	ClinicalTrials.gov (NCT00989404) Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days